SCHEMBL30088909

SCHEMBL30088909

CC(C)(C)OC(=O)N1CCC[C@@H](N(C(N)=O)c2ccc(C#N)nc2)C1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 8/20 0.51
PARP1 P09874 1/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
ALOX5AP P20292 2/20 0.41
FEN1 P39748 2/20 0.41
JAK2 O60674 1/20 0.41
JAK1 P23458 1/20 0.41
USP30 Q70CQ3 2/20 0.40
HPGDS O60760 1/20 0.40
LCK P06239 1/20 0.39
JAK3 P52333 1/20 0.39
BTK Q06187 1/20 0.39
CHEK2 O96017 1/20 0.39
PRMT5 O14744 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27177267 1.00 GPR119 (0.51) GPR119PARP1MEN1ALDH1A1MAPT
SCHEMBL30089186 0.91 GPR119 (0.52) GPR119MEN1ALDH1A1MAPTKMT2A
SCHEMBL27177204 0.85 GPR119 (0.36) GPR119KMT2AJAK2JAK1USP30
SCHEMBL29119904 0.80 ALOX5AP (0.47) GPR119MEN1KMT2AALOX5APFEN1
SCHEMBL30218114 0.80 ALOX5AP (0.47) GPR119MEN1KMT2AALOX5APFEN1
SCHEMBL29119906 0.80 ALOX5AP (0.47) GPR119MEN1KMT2AALOX5APFEN1
SCHEMBL30218474 0.80 ALOX5AP (0.47) GPR119MEN1KMT2AALOX5APFEN1
SCHEMBL30089181 0.78 GPR119 (0.52) GPR119PARP1MEN1ALDH1A1MAPT
SCHEMBL27177227 0.77 GPR119 (0.38) GPR119USP30
SCHEMBL30089042 0.76 GPR119 (0.37) GPR119MEN1ALDH1A1KMT2AJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140933-A1 OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER HOFFMANN-LA ROCHE INC. (US) 2024-05-02 US disclosed
EP-4341252-A1 OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER F. Hoffmann-La Roche AG (CH) 2024-03-27 EP disclosed
WO-2022243346-A1 OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER F. HOFFMANN-LA ROCHE AG (CH) 2022-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140933-A1 OXOINDOLINE COMPOUND FOR THE TREATMENT OF INFLAMMATORY DISEASES OR CANCER IL1B, IL1A, IL1R1 GPR119 619/4885PARP1 906/4885MEN1 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.